
|Articles|June 2, 2022
Daily Medication Pearl: Ritonavir (Norvir)
Author(s)Saro Arakelians, PharmD
Ritonavir (Norvir) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Advertisement
Medication Pearl of the Day: Ritonavir (Norvir)
Indication: Ritonavir (Norvir) tablets and oral solution are HIV protease inhibitors indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Insight:
- Dosing: Adult patients 600 mg twice-daily with meals
- Dosage forms: Tablet 100 mg; oral solution 80 mg per milliliter; oral powder 100 mg per packet.
- Adverse events: The most frequently reported adverse drug reactions among patients receiving ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower), neurological disturbances (including paresthesia and oral paresthesia), rash, and fatigue/asthenia.
- Mechanism of action: Ritonavir is a peptidomimetic inhibitor of the HIV-1 protease. Inhibition of HIV protease renders the enzyme incapable of processing the Gag-Pol polyprotein precursor, which leads to production of non-infectious immature HIV particles.
Reference:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
2
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
3
FDA Approves Targeted Combination Therapy for BRCA2-Mutated Prostate Cancer
4
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
5

















































































































































































































